The Paradigm-HF study showed as the use of a new class of drugs, angiotensin receptors/neprilysin inhibitors (ARNI) in HFrEF patients may reduce cardiovascular death and HF hospitalizations by approximately 20%, compared to standard of care [6]. This evidence concerns the gene MME and hydrops fetalis.